We are live on ! Find out more
SBFMW icon

Sunshine Biopharma Warrant
SBFMW

4 hedge funds and large institutions have $13.3K invested in Sunshine Biopharma Warrant in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0.02% less ownership

Funds ownership: 0.27% → 0.25% (-0.02%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

98% less capital inflows, than outflows

Capital inflows: $22 | Capital outflows: $1.08K

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$22

SBFMW Hedge Fund Activity: Q4 2023 in Review

4 of the 6,880 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma Warrant (SBFMW) for Q4 2023, worth a combined $13.3K — down 14% from $15.4K a quarter earlier.

Fund positioning in SBFMW was balanced in Q4 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 3 trimmed.

The largest buyer was Bank of America, adding an estimated $22. The largest seller was Citadel Advisors, cutting an estimated $930.

  • 4 institutional investors held Sunshine Biopharma Warrant (SBFMW) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $13.3K of Sunshine Biopharma Warrant stock for Q4 2023, down 14% quarter-over-quarter.
  • 0 funds opened new Sunshine Biopharma Warrant positions in Q4 2023 and 0 closed out.
  • The largest Sunshine Biopharma Warrant buyer in Q4 2023 was Bank of America, an estimated $22 added.
  • The largest Sunshine Biopharma Warrant seller in Q4 2023 was Citadel Advisors, an estimated $930 sold.

Based on aggregated 13F filings for Q4 2023.